The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded and managed by NHS England, in partnership with Diabetes UK. The NDA provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations, identify gaps or shortfalls that are priorities for improvement, identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales. This data release includes the care process and treatment target measurements for the full 2023-24 audit period (1 January 2023 – 31 March 2024); presented for England primary care, Wales primary care and specialist services (hospital-based care), each with its own separate data file. Data from primary care in England was collected throughout the audit period. Data for specialist services in England is submitted throughout the year with the January 2023 to March 2024 cut of this data being taken in May 2024. Data from Wales was received in June 2024.

The worksheets include data for all ICBs and GP practices in England within the May 2025 extraction of NDA data (April 2024 to March 2025 data). These data undergo further validation processes at the end of each audit year when data from specialist services are added in, at which point the data are considered to comprise the full annual dataset to be used in the annual NDA publications. Data for Local Health Boards (LHBs) in Wales and specialist diabetes services in England are not included in the quarterly publications. Their 2024-25 data (for the full audit period April 2024 to March 2025) will be extracted as part of the final NDA 2024-25 collection and reported in the NDA 2024-25 full audit period data release, scheduled for late 2025. Disclosure control has been applied to mitigate the risk of patient identification. Zeros are reported, and all numbers are rounded to the nearest 5, unless the number is 1 to 7, in which case it is rounded to ‘5’. This allows for more granular data to be made available, and also for data for all GP practices to be made available. Percentages where the denominator is less than or equal to 20 are not reliable and have therefore not been calculated in this release.

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

North America Insulin Syringe Market size was valued at USD 259 Million in 2024 and is projected to reach USD 290 Million by 2032, growing at a CAGR of 1.7% from 2025 to 2032.

Key Market Drivers:

Increasing Diabetes Prevalence: According to the Centers for Disease Control and Prevention's (CDC) 2022 National Diabetes Statistics Report, more than 37.3 million Americans (or 11.3% of the US population) have diabetes, with roughly 28.7 million diagnosed and 8.5 million undiagnosed. The number of individuals diagnosed with diabetes has more than quadrupled over the previous 20 years, resulting in a significant and rising need for insulin syringes.

Ageing Population Growth: According to the United States Census Bureau, the number of Americans aged 65 and over is expected to reach 77 million in 2034. This age change is especially relevant for the insulin syringe industry, as type 2 diabetes is more common in older persons.

According to Cognitive Market Research, the Blood Glucose Monitoring Devices Market Size will be USD XX Million in 2024 and is set to achieve a market size of USD XX Million by the end of 2033 growing at a CAGR of XX% from 2025 to 2033.

North America held largest share of xx% in the year 2024 
Europe held share of xx% in the year 2024 
Asia-Pacific held significant share of xx% in the year 2024 
South America held significant share of xx% in the year 2024
Middle East and Africa held significant share of xx% in the year 2024 

MARKET DYNAMICS: KEY DRIVERS

Rising prevalence of diabetes to surge the demand for blood glucose monitoring devices market

As a result of an increase in the incidence of diabetes globally, demand for blood glucose monitoring systems is rising sharply. The majority of individuals with diabetes, i.e., more than 90%, suffer from type 2 diabetes, which is driven by urbanisation, an ageing population, physical inactivity, and escalating prevalence rates of being overweight or obese. For example, based on national diabetes statistics report, of the U.S. adults aged 18 years and older, 97.6 million adults 18 years or older have prediabetes (38.0% of the all adult U.S. population) in 2021. As the demand for diabetes cases increases, more patients have to monitor their blood sugar levels on a regular basis in order to control their condition well. This increased demand is leading to the market for blood glucose monitoring devices as they are needed for early diagnosis, constant management, and treatment of diabetes. Also, improvements in technology and increased understanding of diabetes treatment have contributed to making the devices more affordable and easy to use, further enhancing their uptake. Healthcare systems across the globe are emphasising prevention and timely intervention, which raises the need for effective glucose monitoring solutions. In summary, the rising population with diabetes is the most important driver accelerating the growth of the blood glucose monitoring devices market. The incidence of diabetes rises with age, and elderly individuals are more likely to develop diabetes or diabetes-associated complications. When the elderly population size expands, so does the number of people at risk for diabetes, resulting in an enhanced need for blood glucose monitoring instruments.

Source: https://idf.org/about-diabetes/diabetes-facts-figures/

https://www.who.int/news/item/13-11-2024-urgent-action-needed-as-global-diabetes-cases-increase-four-fold-over-past-decades

https://www.cdc.gov/diabetes/php/data-research/

Restraints

The high prices of blood glucose monitoring devices are hampering the growth of blood glucose monitoring market.

The exorbitant price of blood glucose monitoring equipment, particularly continuous glucose monitors, is one of the major hurdles being faced by this market, which is otherwise growing steadily. Most individuals with diabetes are unable to purchase these devices because, in addition to a significant amount of money at the point of purchase, they also have recurring costs for replacement transmitters and sensors. This economic strain makes it difficult for people to regularly check their blood sugar levels, which is essential in the management of diabetes. For instance, most diabetes patients, an estimated 31%, have indicated that they do not check their glucose levels frequently because test strips are too costly. Moreover, almost half of the patients, approximately 47%, find glucose testing inconvenient, further deterring regular monitoring. These issues indicate the extent to which cost and convenience factors are constraining greater use of glucose monitoring technology. Confirming this, the American Diabetes Association (ADA) survey of 2,595 individuals with diabetes showed that one in five avoided or delayed taking up a pump or CGM, with half of these instances having a direct connection to high costs. During the pandemic, 15% of users who depend on these devices delayed replenishing their supplies, and 70% of them did so because of financial hardship. Prices show this issue as well, such as one test strip may range from 27 to 56 US cents, whereas sensors for continuous or flash glucose monitoring devices run anywhere from $88 to $107 per sensor. These expenses quickly add up, and it becomes difficult for most patients to be consistent about their use. Overall, the high expense...

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against the National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This NICE guidance is based on evidence that regular systematic review of people with diabetes and achievement of glucose, blood pressure and cardiovascular risk standards maintains health and reduces long term complications.

North America Sulfonylureas Market size was valued at USD 3.1 Billion in 2024 and is Projected to reach USD 3.9 Billion by 2032, growing at a CAGR of 1.9% from 2025 to 2032.

Key Market Drivers:

Increasing Prevalence of Type 2 Diabetes: According to the Centers for Disease Control and Prevention's (CDC) National Diabetes Statistics Report, approximately 37.3 million Americans (11.3% of the population) had diabetes in 2020, with Type 2 diabetes accounting for 90-95% of cases. This high incidence increases demand for sulfonylureas, which are still one of the most commonly recommended second-line treatments for Type 2 diabetes.

Cost-Effectiveness in Relation to Newer Medications: Sulfonylureas are far more cheap than modern diabetes treatments. According to a research published in the Journal of the American Medical Association (JAMA), the average monthly cost of sulfonylureas was $4-11, whereas newer GLP-1 receptor agonists cost $350-500.

The NHS Diabetes Prevention Programme (DPP) is a joint commitment from NHS England and Diabetes UK to deliver, at scale, evidence based behavioural interventions that can prevent or delay the onset of Type 2 diabetes in adults who have been identified as having non-diabetic hyperglycaemia (NDH). This report presents the national audit findings, summarising registration and demographic information on people registered in GP Practices in England who have non-diabetic hyperglycaemia. Also presented are the numbers of people recorded in GP practices as having been offered DPP behavioural change courses up to the end of March 2025, and the numbers that have declined, or not declined, to attend these courses. Non-diabetic hyperglycaemia involves blood glucose levels that are above normal levels, but not in the diabetic range. This release includes data for Detained Estates. Detained Estates include prisons, young offender institutes, children's homes and immigration removal centres. The report is for England only.

Diabetes Management Devices Market Outlook

The global diabetes management devices market size was valued at approximately USD 26.5 billion in 2023 and is projected to reach around USD 49.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2032. This growth can be attributed to the increasing prevalence of diabetes, coupled with the rising demand for advanced medical technologies to monitor and manage this chronic condition effectively. The global upsurge in diabetic cases, driven by lifestyle changes, aging populations, and genetic predispositions, forms a significant growth factor. Furthermore, the growing awareness regarding self-monitoring of blood glucose and the potential of technology-driven interventions in diabetes care are expected to propel the market forward over the forecast period.

One of the primary growth drivers for the diabetes management devices market is the rising incidence of diabetes worldwide. Sedentary lifestyles, unhealthy dietary habits, and increasing obesity rates have contributed significantly to the growing diabetic population. The World Health Organization (WHO) estimates that by 2030, diabetes will be the seventh leading cause of death. As the prevalence of diabetes rises, the demand for effective management solutions also increases, creating a robust market for diabetes management devices. Innovations in technology, such as continuous glucose monitoring and closed-loop insulin delivery systems, have transformed diabetes management, offering patients more precise control over their blood glucose levels and improving overall quality of life.

Technological advancements in diabetes management devices have led to the development of more sophisticated and user-friendly devices, further driving market growth. The integration of artificial intelligence (AI) and cloud-based solutions has enabled real-time data tracking and personalized treatment plans, enhancing patient engagement and compliance. Moreover, the proliferation of smartphone applications and wearable technologies has made it easier for patients to monitor their glucose levels and insulin administration remotely. These advancements not only improve patient outcomes but also reduce healthcare costs by minimizing complications associated with poor diabetes management, thus boosting the market for diabetes management devices.

Public health initiatives and government support play a crucial role in the expansion of the diabetes management devices market. Many countries have implemented national diabetes prevention and control programs aimed at raising awareness, promoting early diagnosis, and providing access to affordable diabetes care. For instance, the U.S. government's National Diabetes Prevention Program emphasizes lifestyle changes and routine screenings to prevent or delay the onset of type 2 diabetes. Such initiatives increase the adoption of diabetes management devices as part of comprehensive diabetes care strategies. Additionally, favorable reimbursement policies and coverage for diabetes management devices encourage patients to utilize these technologies, further driving market growth.

From a regional perspective, North America currently dominates the diabetes management devices market, owing to its high diabetes prevalence, advanced healthcare infrastructure, and strong presence of key market players. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by a rising diabetic population, increasing healthcare expenditure, and growing awareness about diabetes management. Emerging markets such as India and China present significant opportunities for market expansion due to their large patient populations and improving access to healthcare services. Moreover, the Middle East and Africa region also demonstrate potential for growth, supported by efforts to improve healthcare systems and address the rising burden of diabetes.

The market for Pet Diabetes Care Devices Sales is also witnessing a notable surge, as awareness about diabetes in pets increases among pet owners. With advancements in veterinary medicine, there is a growing emphasis on the health and wellness of pets, including the management of chronic conditions like diabetes. Pet diabetes care devices, such as glucose monitors and insulin delivery systems, are becoming more sophisticated, mirroring the technological progress seen in human diabetes care. This segment is driven by the rising incidence of diabetes in pets, particularly in cats and dogs, which is often linked

The worksheets include data for all ICBs, PCNs and GP practices in England within the February 2023 extraction of NDA data (January to December 2022 data). These data undergo further validation processes at the end of each audit year when data from specialist services are added in, at which point the data are considered to comprise the full annual dataset to be used in the annual NDA publications. Data for Local Health Boards (LHBs) in Wales and specialist diabetes services in England are not included in the quarterly publications. Their 2022-23 data (for the full audit period January 2022 to March 2023) will be reported in the full audit period data release and state of the nation report, scheduled for late 2023 and summer 2024 respectively. Disclosure control has been applied to mitigate the risk of patient identification. Zeros are reported, and all numbers are rounded to the nearest 5, unless the number is 1 to 7, in which case it is rounded to ‘5’. This allows for more granular data to be made available, and also for data for all GP practices to be made available.

No. of Deaths: Caused by: Diabetes Mellitus data was reported at 2,017.000 Person in Sep 2024. This records an increase from the previous number of 2,006.000 Person for Jun 2024. No. of Deaths: Caused by: Diabetes Mellitus data is updated quarterly, averaging 1,951.500 Person from Mar 2017 (Median) to Sep 2024, with 30 observations. The data reached an all-time high of 2,847.000 Person in Jun 2021 and a record low of 1,641.000 Person in Sep 2017. No. of Deaths: Caused by: Diabetes Mellitus data remains active status in CEIC and is reported by National Administrative Department of Statistics. The data is categorized under Global Database’s Colombia – Table CO.G012: Number of Deaths: Cause of Death.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. This is the Type 1 Diabetes report. It details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for people with type 1 diabetes. The 2019-20 audit covers the period 01 January 2019 to 31 March 2020. This is the first NDA report dedicated to people with type 1 diabetes. A new diagnosis validation process, which considers medication as well as recorded diagnosis, has been introduced to try to ensure that only people with true type 1 diabetes are included (see appendix). Results are to be taken in the context of low data submission from specialist services, possibly hampered due to COVID-19.

Glucose Meter Market Outlook

The global glucose meter market size was valued at approximately $12 billion in 2023 and is projected to reach around $21 billion by 2032, exhibiting a robust CAGR of 6.5% from 2024 to 2032. This growth is driven by the increasing prevalence of diabetes, rising health awareness, and technological advancements in glucose monitoring devices. As healthcare systems around the world continue to improve and become more accessible, the demand for reliable and efficient glucose monitoring solutions is expected to surge.

One of the primary growth factors for the glucose meter market is the escalating prevalence of diabetes worldwide. According to the International Diabetes Federation, there were approximately 537 million adults living with diabetes in 2021, a number expected to rise to 643 million by 2030 and 783 million by 2045. This alarming increase necessitates effective management of the condition, thereby boosting demand for glucose meters. The growing aging population, which is more prone to diabetes, also contributes significantly to market growth. Additionally, increasing awareness about diabetes management and preventive healthcare among populations further fuels the market's expansion.

Technological advancements in glucose monitoring devices are another crucial factor propelling the market. The evolution from traditional self-monitoring blood glucose meters to advanced continuous glucose monitoring (CGM) systems has revolutionized diabetes management. CGM systems provide real-time glucose level tracking, reducing the number of finger pricks required and offering better glucose control. Innovations such as non-invasive glucose monitors and the integration of glucose meters with smartphones and wearable technology are also influencing market growth positively. These advancements not only enhance patient compliance and convenience but also allow for better disease management and improved quality of life for diabetic patients.

Furthermore, supportive government initiatives and favorable reimbursement policies play a vital role in the market's growth. Governments and healthcare organizations globally are investing in diabetes care and management programs to mitigate the burden of the disease. For instance, numerous countries have implemented national diabetes plans that include subsidizing glucose monitoring devices, thus making them more accessible to a broader population. These efforts, coupled with increasing healthcare expenditure, significantly support market growth. Additionally, the rise in disposable incomes, particularly in developing regions, has made advanced diabetes management solutions more affordable, hence driving market expansion.

Regionally, North America dominates the glucose meter market owing to the high prevalence of diabetes, advanced healthcare infrastructure, and significant healthcare expenditure. Europe follows closely due to similar factors and a growing aging population. The Asia Pacific region, however, is projected to witness the highest growth rate during the forecast period. Factors such as increasing diabetes incidence, rising healthcare spending, improving healthcare infrastructure, and growing awareness about diabetes management contribute to this trend. With a large population base and increasing urbanization, countries like China and India are becoming significant markets for glucose meters. Meanwhile, Latin America and the Middle East & Africa are also expected to see notable growth, albeit at a slower pace, due to improving healthcare access and rising awareness.

Product Type Analysis

The glucose meter market is segmented based on product type into self-monitoring blood glucose (SMBG) meters and continuous glucose monitoring (CGM) meters. Each of these segments plays a critical role in diabetes management, catering to different patient needs and preferences. SMBG meters are the traditional glucose monitoring devices that require blood samples and provide readings instantly. They are widely used due to their affordability, ease of use, and reliability. These meters remain a popular choice, especially among older patients and those who may not require constant monitoring.

Continuous glucose monitoring (CGM) meters, on the other hand, represent a significant advancement in diabetes care. These devices provide real-time glucose level readings throughout the day and night, offering a more comprehensive picture of glucose trends and patte

Inadequately Controlled Type-II Diabetes Treatment Market Outlook

According to our latest research, the global inadequately controlled Type-II diabetes treatment market size reached USD 27.4 billion in 2024. The market is experiencing robust growth, with a recorded CAGR of 7.1% from 2025 to 2033. By the end of 2033, the market is forecasted to attain a size of USD 51.2 billion. This growth is primarily driven by the rising prevalence of Type-II diabetes worldwide, increasing awareness about the complications associated with poorly managed diabetes, and the continuous innovation in pharmacological therapies aimed at improving glycemic control.

One of the major growth factors propelling the inadequately controlled Type-II diabetes treatment market is the escalating global burden of diabetes, particularly in developing nations. The International Diabetes Federation estimates that over 537 million adults are currently living with diabetes, and a significant proportion of these patients are unable to achieve optimal glycemic control despite existing therapeutic regimens. This unmet clinical need is fueling the demand for advanced treatment options, including novel drug classes and combination therapies. Additionally, the growing adoption of personalized medicine and precision therapies is further enhancing treatment efficacy, thereby attracting substantial investments from both public and private sectors.

Another key driver is the advancement in drug delivery technologies and the introduction of next-generation therapeutics, such as GLP-1 receptor agonists and SGLT2 inhibitors. These therapies have demonstrated superior efficacy in managing blood glucose levels and reducing the risk of diabetes-related complications, especially for patients who have not responded adequately to traditional treatments like sulfonylureas and thiazolidinediones. The increased focus on patient-centric care and the integration of digital health solutions for continuous glucose monitoring are also contributing to improved disease management and better patient outcomes, which in turn is accelerating market growth.

Moreover, favorable reimbursement policies and supportive government initiatives aimed at improving diabetes care infrastructure are playing a pivotal role in market expansion. Several countries have launched national diabetes control programs and are investing in public health campaigns to raise awareness about the importance of timely diagnosis and effective disease management. These initiatives are complemented by the efforts of pharmaceutical companies to expand their product portfolios and strengthen their distribution networks, particularly in emerging markets where the prevalence of inadequately controlled Type-II diabetes is rising at an alarming rate.

From a regional perspective, North America continues to dominate the inadequately controlled Type-II diabetes treatment market, accounting for the largest revenue share in 2024. This can be attributed to the high prevalence of diabetes, early adoption of innovative therapies, and the presence of leading pharmaceutical companies in the region. However, Asia Pacific is expected to witness the fastest growth during the forecast period, driven by rapid urbanization, changing lifestyles, and increasing healthcare expenditure. Europe also holds a significant market share, supported by strong healthcare infrastructure and ongoing research and development activities. The Middle East & Africa and Latin America are emerging as promising markets, with increasing government focus on healthcare access and rising awareness about diabetes management.

Drug Class Analysis

The inadequately controlled Type-II diabetes treatment market is segmented by drug class into insulin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, and others. Among these, insulin remains the cornerstone of therapy for patients who fail to achieve glycemic targets with oral agents. In 2024, insulin accounted for the largest market share, owing to its proven efficacy in lowering blood glucose l

The size of the China Diabetes Drugs And Devices market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of > 3.50% during the forecast period.Diabetes drugs and devices are the tools to manage and control diabetes, this chronic disease that is associated with high levels of blood sugar. They help in controlling insulin production, improve the sensitivity of body cells to insulin, and decrease blood glucose levels directly. Multiple categories of these drugs include oral antidiabetic drugs, newer classes of drugs, GLP-1 receptor agonists, and SGLT-2 inhibitors.Diabetes technologies, to its contrast, may assist an individual with diabetes in monitoring and managing glucose levels in the blood. These include a blood glucose meter, continuous glucose monitoring system, insulin pump, and pen injector. These machines provide patients with actual information regarding their real blood sugar level, thereby allowing them to make proper decisions regarding food intake, exercise, and drug therapy.The market for diabetes drugs and devices in China is one of the largest and fastest-growing in the world.The high growth rate of diabetes patients along with increased health care and access to healthcare has faced great demands for such products. Even further growth in the market has been driven by the Chinese government control over diabetes through various initiatives like the National Diabetes Prevention and Control Program. This demand for drugs and devices in the treatment of diabetes is further elevated by an increasingly old demographic across the Chinese population, which is becoming more sedentary. Recent developments include: April 2023: The National Healthcare Security Administration announced that China's diabetes patients can now access high-quality and more affordable insulin products, as the country's drug bulk-buying program for insulin products led to an average price cut of 48%. The centralized procurement is estimated to save CNY 9 billion (about USD 1.31 billion) in diabetes-related health expenditures yearly., June 2022: LifeScan announced that the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) has published Real World Evidence of Improved Glycemic Control in People with Diabetes using a Bluetooth-connected Blood Glucose Meter with Mobile Diabetes Management Application using the OneTouch Reveal mobile app with the OneTouch Verio Reflect meter- synced via Bluetooth wireless technology could support improved glycemic control for people with diabetes.. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: Continuous Glucose Monitoring Segment Expected to Witness the Highest Growth Rate Over the Forecast Period.

Anti-Diabetic Drugs Market Outlook

The global anti-diabetic drugs market size was valued at approximately USD 58 billion in 2023 and is projected to reach around USD 130 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.3% from 2024 to 2032. The surge in market size can be attributed to several factors, including the increasing prevalence of diabetes worldwide, innovations in drug formulations, and heightened awareness and diagnosis rates. The continuous rise in the number of diabetic patients worldwide, driven by sedentary lifestyles, unhealthy diets, and genetic factors, has necessitated advanced and more efficient anti-diabetic medications, thereby propelling market growth.

A significant growth factor for the anti-diabetic drugs market is the increasing prevalence of diabetes, which is primarily driven by rising obesity rates, sedentary lifestyles, and aging populations. Diabetes is becoming a major public health concern globally, with the International Diabetes Federation estimating that approximately 537 million adults were living with diabetes in 2021, a number that is anticipated to rise substantially by 2030. This dramatic increase in diabetes cases is prompting healthcare professionals and pharmaceutical companies to focus on developing more effective treatment options, thereby driving market growth. Furthermore, advancements in medical research have led to the discovery of new drug classes and treatment combinations, which are expected to become more prevalent in the coming years.

Technological advancements and innovations in drug delivery systems also play a pivotal role in driving the growth of the anti-diabetic drugs market. The development of new drug formulations, including oral insulin and smart insulin pens, has revolutionized diabetes management by improving drug efficacy and patient compliance. For instance, the emergence of continuous glucose monitoring systems that work in conjunction with insulin pumps has significantly improved disease management and patient outcomes. These technological innovations not only enhance the effectiveness of existing drugs but also pave the way for novel therapeutics, thus offering lucrative growth opportunities for market players.

In addition, increasing healthcare expenditure and government initiatives to control diabetes are bolstering the market growth. Several governments and healthcare organizations are implementing national diabetes prevention and control programs, aiming to increase awareness, improve education, and enhance accessibility to medications and healthcare services. These initiatives have led to improved diagnosis rates and increased uptake of anti-diabetic drugs. Moreover, favorable reimbursement policies in developed countries create a supportive market environment, encouraging further research and development in diabetes therapeutics.

As the prevalence of diabetes continues to rise, there is a growing interest in Non-Insulin Therapies for Diabetes. These therapies offer alternative treatment options for patients, particularly those with type 2 diabetes who may not require insulin therapy. Non-insulin therapies include a variety of oral medications and injectables that work through different mechanisms to control blood glucose levels. The development of these therapies is driven by the need for more personalized treatment approaches that cater to individual patient needs and preferences. With advancements in medical research, non-insulin therapies are increasingly being recognized for their potential to improve patient outcomes and enhance quality of life for those living with diabetes.

Regionally, the Asia Pacific is expected to demonstrate the most significant growth in the anti-diabetic drugs market. The region's robust growth is fueled by its large population base, increasing urbanization, and rising prevalence of diabetes. Countries like India and China are seeing a rapid increase in diabetic populations due to changes in lifestyle and dietary habits. Furthermore, economic development in these regions has led to increased healthcare expenditure and improvements in healthcare infrastructure, which in turn support market expansion. North America, on the other hand, remains the largest market for anti-diabetic drugs, driven by advanced healthcare systems, high awareness levels, and a strong presence of major pharmaceutical companies.

Drug Class Analysis

The anti-diabetic drugs market is segmented by drug class, which includes i

The Harmonised Data in Five National Longitudinal Cohort Studies project, supported by the Economic and Social Research Council (ESRC), brings together data from five British cohort studies: the 1946 National Survey of Health and Development (NSHD), the 1958 National Child Development Survey (NCDS), the 1970 British Cohort Study (BCS70), Next Steps (formerly the Longitudinal Study of Young People in England), and the Millennium Cohort Study (MCS). NCDS, BCS70, Next Steps, and MCS receive core funding from the ESRC and are hosted by the Centre for Longitudinal Studies at UCL. NSHD is funded by the Medical Research Council (MRC) and is hosted by the Unit for Lifelong Health and Ageing at UCL.

The Diabetes Harmonisation project aimed to document all self-reported measures related to diabetes in these five British cohort studies and produce harmonised indicators of self-reported diabetes through retrospective harmonisation. This harmonisation serves two primary purposes: improving the measurement of diabetes (as an outcome, predictor, or control variable) within cohort analyses, and facilitating cross-cohort research on diabetes using these rich datasets.

Separate longitudinal datasets were created for each cohort, focusing on self-reported data with some information derived from doctors' reports and medical records. Biomarkers and linked health data were not included. Focus was given to measures that were administered to entire cohorts only and on the diabetes status of cohort members themselves (not their parents or children).

Harmonised diabetes data for the MRC National Survey of Health and Development are available under Special Licence from SN 9421.

Type 1 Diabetes Therapeutics Market Outlook

According to our latest research, the global Type 1 Diabetes Therapeutics market size in 2024 stands at USD 9.7 billion, reflecting the growing burden of type 1 diabetes worldwide and the increasing adoption of advanced therapeutics. The market is expected to witness a robust CAGR of 7.1% from 2025 to 2033, reaching a projected value of USD 18.1 billion by 2033. This impressive growth trajectory is primarily fueled by technological advancements in insulin delivery systems, rising disease prevalence, and increased awareness about effective diabetes management. As per our latest research, the market’s expansion is further supported by continuous innovation in drug formulations and supportive healthcare policies across key regions.

One of the most significant growth factors driving the Type 1 Diabetes Therapeutics market is the persistent rise in the incidence and prevalence of type 1 diabetes, particularly among children and young adults. The increasing number of newly diagnosed cases globally has created a surge in demand for effective and accessible treatment options. Moreover, the growing awareness among patients and caregivers about the long-term complications of poorly managed diabetes has led to higher adoption rates of advanced therapies, including continuous glucose monitoring and ultra-long-acting insulins. The market is also benefitting from extensive research and development activities aimed at improving the efficacy and safety profile of existing therapeutics, which has resulted in a steady pipeline of novel drugs and delivery devices.

Another crucial driver is the technological innovation in insulin delivery systems, which has revolutionized the management of type 1 diabetes. The introduction of smart insulin pens, patch pumps, and closed-loop artificial pancreas systems has significantly enhanced patient convenience, adherence, and glycemic control. These advancements are particularly impactful in developed markets where reimbursement policies support the adoption of high-cost devices. Additionally, collaborations between pharmaceutical companies and technology firms are accelerating the development of next-generation therapeutics and digital health solutions, further propelling market growth. The integration of telemedicine and mobile health applications into diabetes care is also expanding access to personalized and remote management, especially in regions with limited healthcare infrastructure.

The global Type 1 Diabetes Therapeutics market is also influenced by favorable government initiatives and increasing healthcare expenditure. Many countries are implementing national diabetes programs and subsidizing the cost of insulin and other essential medicines, making treatment more accessible to a broader population. Furthermore, the emergence of biosimilar insulins has introduced cost-effective alternatives, driving competition and expanding patient access. The presence of well-established distribution networks, particularly in developed economies, ensures the timely availability of therapeutics and supports market penetration. However, disparities in healthcare access and affordability in low- and middle-income countries remain a challenge that the industry must address to achieve equitable growth.

Regionally, North America dominates the Type 1 Diabetes Therapeutics market due to its high disease prevalence, advanced healthcare infrastructure, and strong presence of leading pharmaceutical companies. Europe follows closely, with significant investments in diabetes research and robust reimbursement frameworks. The Asia Pacific region is emerging as a lucrative market, driven by rising awareness, improving healthcare systems, and a growing diabetic population. Latin America and the Middle East & Africa are witnessing gradual growth, supported by government initiatives and increasing access to essential medicines. The regional outlook highlights the need for tailored strategies to address the unique challenges and opportunities in each market segment.

Drug Class Analysis

The Drug Class segment of the Type 1 Diabetes Therapeutics market is primarily categorized into Insulin, Amylin Analogs, and Others. Insulin remains the cornerstone of type 1 diabetes management, accounting for the largest market share within this segment. The continuous innovation in insulin formulations, such as rapid-acting, long-acting, and ultra-long-acting

Insulin Delivery Devices Market Outlook

As per our latest research, the global insulin delivery devices market size reached USD 17.8 billion in 2024, and is expected to grow at a robust CAGR of 7.5% from 2025 to 2033. By the end of the forecast period, the market is projected to attain a value of USD 34.1 billion in 2033, driven by the surging prevalence of diabetes, increasing adoption of advanced insulin delivery technologies, and growing awareness regarding diabetes management. The market’s upward trajectory is further supported by continuous product innovation and a rising geriatric population globally.

One of the primary growth factors for the insulin delivery devices market is the escalating global burden of diabetes, particularly type 1 and insulin-dependent type 2 diabetes. The World Health Organization reports that the number of adults living with diabetes has nearly quadrupled since 1980, and this trend shows no signs of abating. This increase is attributed to changing lifestyles, urbanization, unhealthy dietary habits, and rising obesity rates. As a result, there is an ever-increasing demand for efficient, user-friendly, and safe insulin delivery devices that can help patients manage their blood glucose levels effectively. The market has responded with a proliferation of innovative devices such as smart insulin pens and wearable insulin pumps, making diabetes management more accessible and less invasive for patients.

Technological advancements represent another significant driver for the insulin delivery devices market. The integration of digital health technologies, such as Bluetooth-enabled insulin pens and automated insulin delivery systems, has revolutionized diabetes care. These advancements offer real-time monitoring, dose tracking, and data sharing capabilities, empowering both patients and healthcare providers to make informed decisions. Furthermore, the emergence of closed-loop insulin delivery systems, often referred to as artificial pancreas systems, is transforming the treatment landscape by automating insulin dosing and reducing the risk of hypoglycemia. Such innovations not only enhance patient adherence but also improve clinical outcomes, thereby fueling market growth.

Government initiatives and increased healthcare expenditure on diabetes management have also played a pivotal role in expanding the insulin delivery devices market. Many countries are implementing national diabetes programs, subsidizing the cost of insulin and related devices, and promoting early diagnosis and treatment. Additionally, favorable reimbursement policies in developed regions, coupled with growing investments by private players in research and development, are accelerating the adoption of advanced insulin delivery solutions. The market is also witnessing a surge in home-based care, as patients seek convenience and autonomy in managing their condition, further boosting demand for portable and easy-to-use devices.

From a regional perspective, North America continues to dominate the global insulin delivery devices market, accounting for the largest revenue share in 2024. This is primarily due to the high prevalence of diabetes, well-established healthcare infrastructure, and rapid adoption of advanced medical technologies in the region. Europe follows closely, driven by increasing healthcare expenditure and supportive government policies. Meanwhile, the Asia Pacific region is emerging as the fastest-growing market, propelled by a large diabetic population, rising awareness, and improving access to healthcare services. Latin America and the Middle East & Africa are also experiencing steady growth, supported by increasing investments in healthcare and expanding distribution networks.

Product Type Analysis

The product type segment of the insulin delivery devices market is broadly categorized into insulin pens, insulin pumps, insulin syringes, insulin jet injectors, and others. Among these, insulin pens have emerged as the most popular choice, owing to their

Hyperglycemia Drugs Market Outlook

According to our latest research, the global hyperglycemia drugs market size reached USD 23.4 billion in 2024, with a robust year-on-year growth rate. The market is expected to expand at a CAGR of 7.3% from 2025 to 2033, projecting a value of approximately USD 44.1 billion by 2033. This impressive growth is primarily driven by the escalating prevalence of diabetes worldwide, rising awareness about hyperglycemia management, and continuous advancements in drug development and delivery technologies.

One of the most significant growth factors for the hyperglycemia drugs market is the alarming surge in diabetes cases globally. The World Health Organization (WHO) estimates that over 537 million adults were living with diabetes in 2024, and this number is expected to rise steadily over the next decade. Urbanization, sedentary lifestyles, and unhealthy dietary habits are major contributors to this trend, leading to a larger patient pool requiring effective hyperglycemia management. As a result, pharmaceutical companies are investing heavily in research and development to introduce innovative drugs that offer better glycemic control, fewer side effects, and improved patient compliance. Furthermore, the increasing incidence of obesity and metabolic disorders further fuels the demand for hyperglycemia drugs, as these conditions are closely linked to impaired glucose regulation and heightened risk of complications.

Technological advancements in drug formulation and delivery systems are another major driver propelling market growth. The introduction of next-generation insulin analogs, oral antidiabetic agents, and combination therapies has revolutionized the treatment landscape for hyperglycemia. These innovations not only offer enhanced efficacy but also improve convenience and adherence, especially with the advent of once-weekly injectable GLP-1 receptor agonists and user-friendly insulin pens. Additionally, digital health tools such as continuous glucose monitoring (CGM) devices and smart insulin pumps are being integrated with drug therapies to enable personalized treatment regimens and real-time monitoring, thereby optimizing therapeutic outcomes and reducing the risk of complications. These technological breakthroughs are expected to further expand the adoption of hyperglycemia drugs across diverse patient demographics.

Government initiatives and supportive healthcare policies play a crucial role in shaping the hyperglycemia drugs market. Many countries have implemented national diabetes management programs, reimbursement policies, and awareness campaigns to promote early diagnosis and effective treatment of hyperglycemia. For instance, the United States, several European countries, and emerging economies in Asia Pacific have prioritized diabetes care as a public health imperative, resulting in increased funding for research, improved access to medications, and the establishment of specialized diabetes care centers. These efforts not only enhance patient outcomes but also create a favorable environment for pharmaceutical companies to introduce novel therapies and expand their market presence.

Regionally, North America continues to dominate the hyperglycemia drugs market, accounting for the largest revenue share in 2024. This leadership is attributed to the high prevalence of diabetes, advanced healthcare infrastructure, and strong presence of leading pharmaceutical companies. Europe follows closely, supported by robust government initiatives and a growing diabetic population. However, Asia Pacific is emerging as the fastest-growing region, driven by rapid urbanization, increasing healthcare expenditure, and rising awareness about diabetes management. Countries such as China, India, and Japan are witnessing a surge in demand for hyperglycemia drugs, making the region a key focus area for market players seeking expansion opportunities.

Drug Class Analysis

The hyperglycemia drugs market is segmented by drug class into Insulin, Sulfonylureas, Biguanides, Thiazolidinediones, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Others. Among these, insulin continues to hold the largest market share, accounting for a significant portion of global revenues in 2024. This dominance is largely due to the critical role of insulin therapy in the management of both type 1 and advanced type 2 diabetes. The development of ultra-long-acting, rapid-acting, and biosimilar insulin products has broadened treatment options, offering be